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LETTER TO THE EDITOR
U-47700 Reply
We appreciate the comments by Dr. Vo et al. for our
recent case report regarding U-47700.[1] They suggest that
the patient we described likely ingested a benzodiazepine
that we did not test for, rather than U-47700 having
caused a false positive on the drug screen used. As we
demonstrated in the report, U-47700 itself can cause a
false positive result on the screen used, but only at very
high concentration. Therefore, we opined that the positive
benzodiazepine screen resulted either from a metabolite of
U-47700 or the presence of a benzodiazepine we did not
test for. Although the patient denied having used other
drugs, histories are not always accurate. Similarly, generaliz-
ing drug use patterns to an individual is not necessarily
accurate either. Based on the case they describe, we retro-
spectively reviewed the ultra-performance liquid chromatog-
raphy time-of-flight mass spectometry data on the patient
we reported and neither found the presence of phenaze-
pam, nor its metabolite 3-hydroxyphenazepam (i.e., no
matching exact mass data for either of these compounds).
It still remains possible that another untested for benzodi-
azepine may have been present.
At the time of publication, due to the lack of reference
standard, we were not able to definitively identify U-47700.
Subsequent to publication, we obtained a reference stand-
ard through Cayman Chemicals (Ann Arbor, MI) and based
on a retention time match and high-resolution mass
spectrometry data, we confirmed U-47700 was the drug
used.
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